Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab

Dmitry Nedosekin, PhD, Kelsey Derrick Wilson, MD, Katelynn Campbell, MD, Sara Shalin, MD, PhD, and Henry K. Wong, MD, PhD
Little Rock, Arkansas

Key words: blistering disorder; bullous pemphigoid; dapsone; immunobullous; immunologic overlap; linear IgA; rituximab.

INTRODUCTION
Autoimmune subepidermal blistering diseases are caused by immunological loss of tolerance to components of hemidesmosomes, triggering humoral and cellular responses. C3 and IgG deposition along the basement membrane zone is characteristic of bullous pemphigoid (BP) [1,2]. Alternately, IgA deposition at the basement membrane zone is consistent with linear IgA bullous dermatosis (LABD) [1,3]. An immunological overlap spanning the clinical and immunologic spectrum between BP and LABD has been reported and referred to as linear IgA/IgG bullous dermatosis (LAGBD) [3,4]. LAGBD has a unique clinical presentation, immunologic properties, and distinct therapeutic options [1,5-7] including rituximab.

CASE REPORT
A 43-year-old African American man presented with a 7-month history of a worsening erythematous and pruritic rash, which had progressed to blisters and ocular pain 4 weeks prior the presentation. Topical triamcinolone and 2 weeks of 60 mg prednisone had failed to improve the rash. The patient denied any medication changes, history of malignancy, autoimmune disease, or inflammatory bowel disease. Past medical history was significant for end-stage renal disease secondary to hypertension (on hemodialysis) and obstructive sleep apnea. Medications included clonazepam, promethazine, metoprolol, and gabapentin. Physical examination showed numerous erosions with collarettes of scale and tense bullae in “string of pearls” annular configurations on the bilateral arms, thighs, and trunk (Fig 1, A and B). Mucosal involvement included sloughing of the left eye conjunctiva and tongue.

Histopathology from skin biopsies with hematoxylin-eosin stain and direct immunofluorescence microscopy was consistent with BP, demonstrating a subepidermal split, an eosinophil-rich inflammatory infiltrate (Fig 2), strong linear C3 deposition, equivocal IgG, and absent IgA along the basement membrane zone. However, indirect immunofluorescence with salt split skin revealed both linear IgG and IgA at the roof of the induced blister (epidermal staining pattern). Enzyme-linked immunosorbent assay was positive for circulating anti-BP180 antibodies in the patient’s serum, with IgG and IgA titers of 1:160 and 1:20, respectively. Anti-BP230 antibodies were absent.

After an additional 2 weeks of prednisone without improvement, the patient was started on rituximab 375 mg/m² weekly for 4 weeks and mycophenolate mofetil 500 mg twice daily. Prednisone was increased to 80 mg (0.5 mg/kg body weight). Dapsone was avoided due to anemia; methotrexate was avoided due to end-stage renal disease and...
morbid obesity. Gabapentin was discontinued due to the possibility of drug-induced BP. Ophthalmology recommended prednisolone acetate ophthalmic suspension, and tobramycin, and dexamethasone ointments. Age-appropriate cancer and autoimmune disease screenings were recommended. Bullae completely cleared after 4 rituximab infusions (Fig 1, C), and prednisone was tapered over a month. The disease relapsed 9 months after initial treatment, but cleared with 2 additional rituximab infusions.

DISCUSSION

Autoimmune subepidermal blistering diseases are rare. The BP incidence is 6-13 per million and may present both in children and adults. A review of 45 LAGBD cases in Japan showed that 49% of the patients were younger than 60 years of age. In BP, the most common antigens are BP230 (a 230-kDa intracellular protein) and BP180 (a 180-kDa transmembrane glycoprotein). Antibodies against BP180 are believed to induce the initial blisters, while anti-BP230 antibodies enhance the inflammatory reaction. In LABD, the target antigens are the 97-kDa or 120-kDa fractions of BP180 carboxy-terminus. In LAGBD, IgG and IgA antibodies target BP180 most commonly, and, less often, laminin-332 and BP230. Drug-induced BP and LABD have been reported; there is, however, no specific association of LAGBD with drugs.
LAGBD has been reported in patients with ulcerative colitis,13 B-cell lymphoma, 17 and colorectal carcinoma.11

Clinical manifestations of BP and LABD are variable and can overlap. LAGBD presentations include erythema,10,14 pustules,14 tense bullous lesions7,10-12,16,17 and small vesicles in annular patterns.10,13,16 Ocular and oral mucosa 7,11 involvement, as well as a case of LAGBD-related interstitial pneumonia,19 have been reported. The relationship between LAGBD clinical manifestations and the type of predominant antibody highlights that BP, LAGBD, and LABD are on a spectrum.20

Histopathologic evaluation shows subepidermal bullae.1 Eosinophilic spongiosis and/or dermal infiltrate of eosinophils are seen in BP. LABD shows predominantly neutrophilic infiltrates.1 LAGBD has mixed eosinophilic and neutrophilic infiltrates.10,11,13,15 Direct immunofluorescence typically reveals the presence of linear deposits of IgG, IgA, and C3. LAGBD has been reported to have IgA and IgG binding mostly to the epidermal surface (as seen in this case),10,12-14,17,21 and rarely combined epidermal-dermal11,15 or dermal16 sides.

Treatment starts with a review of medications to identify and discontinue drugs potentially inducing the disease.1,8 Age-appropriate screening for malignancy may be appropriate.11 Systemic and topical corticosteroids are first-line treatment1-2; however, significant side effects are common. Dapsone treatment is an effective option in LAGBD, limiting systemic immunosuppression.2,7,13,16,17

**Table I.** Comparison of clinical, histological, and immunological findings in BP, LAGBD, and LABD

| Epidemiology | Linear IgA/IgG bullous dermatosis (LAGBD) | Linear IgA bullous dermatosis (LABD) |
| --- | --- | --- |
| 6-13 cases per million | 6.7% of the patients | 0.3-2.3 cases per million |
| Onset over 60 years of age | 42.3% 15-60 years of age | Childhood disease with mean age of 4.5 years; adult disease onset >60 years |
| Mean presentation age, 80 years | 51% >60 years7 | |

**Associated conditions/triggers**

- Medications
- Autoimmune diseases
- Neurological diseases
- Trauma, burns, UV radiation

**Pathogenesis (autoantibodies)**

- BP180
- BP230
- Laminin-33211,15,16

**Clinical presentation**

- Pruritus
- Tense blisters and vesicles
- Erosions and crusting
- Urticarial and infiltrated papules and plaques
- Oral involvement in 10%-30%
- Eye, nose, pharynx, esophagus, and anogenital involvement is rare

**Pathology findings**

- Mixed eosinophilic and neutrophilic infiltrate

**Direct Immunofluorescence**

- IgG and/or C3

**Indirect Immunofluorescence**

- IgG
- Mainly epidermal pattern
- Combined epidermal/dermal pattern

**Mixed eosinophilic and neutrophilic infiltrate**

- IgG + IgA and/or C3
- IgG and IgA
- Mainly epidermal pattern
- Combined epidermal/dermal pattern
- Rarely dermal pattern

**Neutrophilic infiltrate**

- IgA and/or C3
- IgA
- Mainly epidermal pattern
- Combined epidermal/dermal pattern
- Rarely dermal pattern

BP, Bullous pemphigoid; LAGBD, linear IgA/IgG bullous dermatosis; LABD, linear IgA bullous dermatosis.
inhibits neutrophil adhesion and release of tissue-damaging oxidants and proteases. Side effects include hemolytic anemia, methemoglobinemia, neutropenia, neuropathy, and hepatitis. It is contra-indicated for patients with anemia (as in our case), liver disease, or low glucose-6-phosphate dehydrogenase enzyme levels.

Steroid-sparing adjunctive therapies include azathioprine, mycophenolate mofetil, intravenous immunoglobulin, and targeted therapies such as rituximab, an anti-CD20 monoclonal antibody. Rituximab is Food and Drug Administration-approved for the treatment of pemphigus vulgaris. Case reports describe rituximab use for both BP and LABD with higher efficacy observed in IgG-dominant disease. In BP, rituximab has a reported complete response rate of 85%, a recurrence rate of 29%, and an adverse effects rate of 24%. Side effects include infections, anemia, syndrome of inappropriate antidiuretic hormone secretion, drug fever, acute pruritus, peripheral arterial occlusive disease, and tachycardia. Rituximab is an important treatment option for patients with multiple medical comorbidities and severe disease as presented in this case report.

The case presented here highlights the importance of distinguishing between BP, LABD, and LAGBD (Table I). The young age of the patient, mucosal involvement, and bullae in an annular configuration were not typical for classic BP. Only by further evaluation with indirect immunofluorescence and enzyme-linked immunosorbent assay were IgA antibodies identified. The LAGBD diagnosis allows treatment with dapsone (not readily used for BP) or rituximab in severe cases. Due to distinct clinical features, immunologic findings, and treatment modalities, it is important for LAGBD to be recognized as a subtype of subepidermal blistering disease.

Conflicts of interest

Henry K. Wong discloses contracted research for Solegenix, Abbot Laboratories, and Galderma. Dmitry Nedosekin, Kelsey Derrick Wilson, Katelynn Campbell, and Sara Shalin have no conflicts of interest to disclose.

REFERENCES

1. Bologna J, Schaffer JV, Cerroni L. Dermatology. 4th ed. China: Elsevier; 2018.
2. Mihályi L, Kiss M, Dobozj A, Kemény L, Husz S. Clinical relevance of autoantibodies in patients with autoimmune bullous dermatosis. Clin Dev Immunol. 2012;2012:369546.
3. Hashimoto T, Tsuruta D, Koga H, et al. Summary of results of serological tests and diagnoses for 4774 cases of various autoimmune bullous diseases consulted to Kurume University. Br J Dermatol. 2016;175(5):953-965.
4. Csobera K, Schmidt S, Florea F, et al. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases. Orphanet J Rare Dis. 2011;6:31.
5. Izaki S, Ito K, Ishii N, Hashimoto T, Fujita H, Terui T. Infantile linear IgA/IgG bullous dermatosis. Eur J Dermatol. 2016;26(1):96-98.
6. Wozel G, Blasum C. Dapsone in dermatology and beyond. Arch Dermatol Res. 2014;306(2):103-124.
7. Passos L, Rabelo RF, Matsuo C, Santos M, Talhari S, Talhari C. Linear IgA/IgG bullous dermatosis: successful treatment with dapsone and mycophenolate mofetil. An Bras Dermatol. 2011;86(4):747-750.
8. Flamm A, Sachdev S, Dufresne F. Gabapentin-induced bullous pemphigoid. J Am Osteopath Assoc. 2017;117(3):191-193.
9. Horiguchi Y, Ikoma A, Sakai R, Masatsuji A, Ohta M, Hashimoto T. Linear IgA dermatosis: report of an infantile case and analysis of 213 cases in Japan. J Dermatol. 2008;35(11):737-743.
10. Inamura E, Nishie W, Yamaguchi Y, et al. Linear IgA/IgG bullous dermatosis with autoantibodies directing the native and processed forms of BP180. Br J Dermatol. 2020;182:1061-1062.
11. Sakaguchi M, Bito T, Oda Y, et al. Three cases of linear IgA/IgG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332. JAMA Dermatol. 2013;149(11):1308-1313.
12. Metz BJ, Ruggeri SY, Hsu S, et al. Linear IgA dermatosis with IgA and IgG autoantibodies to the 180 kDa bullous pemphigoid antigen (BP180): evidence for a distinct subtype. Int J Dermatol. 2004;43(6):443-446.
13. Onoe A, Matsura D, Terui T, Ishi N, Hashimoto T, Ochiai T. Linear immunoglobulin A/G bullous dermatosis associated with ulcerative colitis. J Dermatol. 2017;44(11):1295-1298.
14. Matsumoto T, Nakamura S, Ishii N, et al. Erythrodermic linear IgA/IgG bullous dermatosis. Eur J Dermatol. 2019;29(2):220-221.
15. Li X, Tsuchisaka A, Qian H, et al. Linear IgA/IgG bullous dermatosis reacts with multiple laminins and integrins. Eur J Dermatol. 2015;25(5):418-423.
16. Izaki S, Mitsuya J, Okada T, Koga H, Hashimoto T, Terui T. A case of linear IgA/IgG bullous dermatosis with anti-laminin-332 autoantibodies. Acta Derm Venereol. 2015;95(3):359-360.
17. Morita K, Fujisawa A, Yagi Y, et al. Immunoglobulin A anti-BP230 autoantibodies in linear immunoglobulin A/immunoglobulin G bullous dermatosis. J Dermatol. 2011;38(10):1030-1032.
18. Kukugawa T, Tomimura S, Hayashi T, et al. Interstitial pneumonia associated with linear immunoglobulin A/immunoglobulin G bullous dermatosis. Respir. 2013;86(4):347-351.
19. Lamberts A, Everman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol. 2018;9:248.
20. Li Z, Jing K, Li S, Feng S. Antigen recognition in the pathogenesis of immunoglobulin A-related autoimmune bullous diseases. Postepy Dermatol Alergol. 2018;35(4):338-343.
21. Cozanni E, Drosar M, Parodi A, Carrozzo M, Gandolfo S, Rebora A. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid. Acta Derm Venereol. 2004;84(3):381-384.
22. Kremer N, Snast I, Cohen ES, et al. Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature. Am J Clin Dermatol. 2019;20(2):209-216.